Logo image of INZY

INOZYME PHARMA INC (INZY) Stock Fundamental Analysis

NASDAQ:INZY - Nasdaq - US45790W1080 - Common Stock - Currency: USD

3.98  0 (0%)

After market: 3.99 +0.01 (+0.25%)

Fundamental Rating

1

Taking everything into account, INZY scores 1 out of 10 in our fundamental rating. INZY was compared to 558 industry peers in the Biotechnology industry. Both the profitability and financial health of INZY have multiple concerns. INZY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INZY had negative earnings in the past year.
In the past year INZY has reported a negative cash flow from operations.
INZY had negative earnings in each of the past 5 years.
In the past 5 years INZY always reported negative operating cash flow.
INZY Yearly Net Income VS EBIT VS OCF VS FCFINZY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

INZY has a Return On Assets of -112.14%. This is in the lower half of the industry: INZY underperforms 79.93% of its industry peers.
INZY has a Return On Equity of -335.61%. This is in the lower half of the industry: INZY underperforms 74.19% of its industry peers.
Industry RankSector Rank
ROA -112.14%
ROE -335.61%
ROIC N/A
ROA(3y)-55.48%
ROA(5y)-49.12%
ROE(3y)-94.58%
ROE(5y)-74.24%
ROIC(3y)N/A
ROIC(5y)N/A
INZY Yearly ROA, ROE, ROICINZY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INZY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INZY Yearly Profit, Operating, Gross MarginsINZY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, INZY has more shares outstanding
The number of shares outstanding for INZY has been increased compared to 5 years ago.
Compared to 1 year ago, INZY has a worse debt to assets ratio.
INZY Yearly Shares OutstandingINZY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
INZY Yearly Total Debt VS Total AssetsINZY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -6.70, we must say that INZY is in the distress zone and has some risk of bankruptcy.
INZY's Altman-Z score of -6.70 is on the low side compared to the rest of the industry. INZY is outperformed by 65.95% of its industry peers.
A Debt/Equity ratio of 0.65 indicates that INZY is somewhat dependend on debt financing.
INZY has a Debt to Equity ratio of 0.65. This is in the lower half of the industry: INZY underperforms 74.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Altman-Z -6.7
ROIC/WACCN/A
WACCN/A
INZY Yearly LT Debt VS Equity VS FCFINZY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

INZY has a Current Ratio of 2.19. This indicates that INZY is financially healthy and has no problem in meeting its short term obligations.
INZY has a Current ratio of 2.19. This is in the lower half of the industry: INZY underperforms 73.66% of its industry peers.
INZY has a Quick Ratio of 2.19. This indicates that INZY is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INZY (2.19) is worse than 71.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.19
INZY Yearly Current Assets VS Current LiabilitesINZY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for INZY have decreased strongly by -24.44% in the last year.
EPS 1Y (TTM)-24.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

INZY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.25% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.85%
EPS Next 2Y13.47%
EPS Next 3Y10.89%
EPS Next 5Y25.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INZY Yearly Revenue VS EstimatesINZY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
INZY Yearly EPS VS EstimatesINZY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INZY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INZY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INZY Price Earnings VS Forward Price EarningsINZY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INZY Per share dataINZY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.47%
EPS Next 3Y10.89%

More info and screens

0

5. Dividend

5.1 Amount

INZY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOZYME PHARMA INC

NASDAQ:INZY (6/4/2025, 8:00:02 PM)

After market: 3.99 +0.01 (+0.25%)

3.98

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners92.16%
Inst Owner Change-8.43%
Ins Owners0.09%
Ins Owner Change1.97%
Market Cap256.95M
Analysts85.33
Price Target13.77 (245.98%)
Short Float %6.07%
Short Ratio1.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.46%
Min EPS beat(2)-5.86%
Max EPS beat(2)0.94%
EPS beat(4)2
Avg EPS beat(4)-0.85%
Min EPS beat(4)-10.77%
Max EPS beat(4)12.28%
EPS beat(8)4
Avg EPS beat(8)2.8%
EPS beat(12)8
Avg EPS beat(12)6.64%
EPS beat(16)11
Avg EPS beat(16)5.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25%
EPS NQ rev (1m)-2.9%
EPS NQ rev (3m)11.83%
EPS NY rev (1m)-0.48%
EPS NY rev (3m)9.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.08
P/tB 8.08
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-1.15
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS0
BVpS0.49
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -112.14%
ROE -335.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.48%
ROA(5y)-49.12%
ROE(3y)-94.58%
ROE(5y)-74.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.08%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 2.19
Altman-Z -6.7
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)33.18%
Cap/Depr(5y)83.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.79%
EPS Next Y12.85%
EPS Next 2Y13.47%
EPS Next 3Y10.89%
EPS Next 5Y25.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-55.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.28%
OCF growth 3YN/A
OCF growth 5YN/A